5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
Open Access
- 15 September 2011
- journal article
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 105
- https://doi.org/10.1186/1741-7015-9-105
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate CancerJournal of Urology, 2011
- Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control StudyPLOS ONE, 2011
- Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination SurveyJournal of Clinical Oncology, 2010
- Statin medication use and the risk of biochemical recurrence after radical prostatectomyCancer, 2010
- Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient PopulationsPharmacoEconomics, 2010
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?Journal of Clinical Oncology, 2010
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJAMA, 2009
- Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active SurveillanceJournal of Urology, 2008
- Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling ApproachCancer Prevention Research, 2008